Kura Oncology (KURA) Convertible Debt (2014)

Kura Oncology (KURA) reported Convertible Debt of $500000.0 for Q4 2014.

Kura Oncology (KURA) Convertible Debt (2014) Analysis & Trends

Kura Oncology (KURA) has 1 years of Convertible Debt data on file, last reported at $500000.0 in Q4 2014.

  • Convertible Debt for Q4 2014 came in at $500000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2014 was $500000.0 (changed N/A YoY), and the FY2014 annual result was $500000.0, changed N/A from the prior year.
  • Convertible Debt steadied at $500000.0 in Q4 2014 per KURA's latest filing.
  • Over five years, Convertible Debt peaked at $500000.0 in Q4 2014 and troughed at $500000.0 in Q4 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Kura Oncology 883.44 Mn 883.44 Mn 18.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2014 500,000.00